FDA Accepts Krystal Biotech's Biologics License Application for Dystrophic Epidermolysis Bullosa

Author's Avatar
Aug 18, 2022
  • FDA granted Priority Review designation

  • PDUFA target action date is February 17, 2023

  • FDA stated that it is not currently planning to hold an advisory committee meeting